SCREENING
Blood test after surgery predicts recurrence in metastatic colorectal cancer — Cancer Treatment Reviews
A systematic review and meta-analysis found that detecting circulating tumor DNA (ctDNA) after surgery for metastatic colorectal cancer strongly predicts which patients will experience recurrence. This molecular residual disease (MRD) detection could help identify patients who need more aggressive follow-up or additional treatment after surgery intended to cure their disease.
What this means
If you've had surgery to remove metastatic colorectal cancer, a blood test for ctDNA may help your team predict your risk of the cancer coming back and tailor your follow-up care accordingly.